CA3178633A1 - Compose et composition pour induire une neuroprotection - Google Patents

Compose et composition pour induire une neuroprotection

Info

Publication number
CA3178633A1
CA3178633A1 CA3178633A CA3178633A CA3178633A1 CA 3178633 A1 CA3178633 A1 CA 3178633A1 CA 3178633 A CA3178633 A CA 3178633A CA 3178633 A CA3178633 A CA 3178633A CA 3178633 A1 CA3178633 A1 CA 3178633A1
Authority
CA
Canada
Prior art keywords
tetramethyl
oxo
oxazaphosphinan
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3178633A
Other languages
English (en)
French (fr)
Inventor
Gilles Rubinstenn
Tangui Maurice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Ecole Pratique des Hautes Etudes SAS
Rest Therapeutics SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Ecole Pratique des Hautes Etudes SAS
Rest Therapeutics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73013493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3178633(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Montpellier, Ecole Pratique des Hautes Etudes SAS, Rest Therapeutics SAS filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of CA3178633A1 publication Critical patent/CA3178633A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3178633A 2020-05-20 2021-05-20 Compose et composition pour induire une neuroprotection Pending CA3178633A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2005138A FR3110393B1 (fr) 2020-05-20 2020-05-20 Compose et composition pour induire une neuroprotection
FRFR2005138 2020-05-20
PCT/FR2021/050929 WO2021234324A1 (fr) 2020-05-20 2021-05-20 Compose et composition pour induire une neuroprotection

Publications (1)

Publication Number Publication Date
CA3178633A1 true CA3178633A1 (fr) 2021-11-25

Family

ID=73013493

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3178633A Pending CA3178633A1 (fr) 2020-05-20 2021-05-20 Compose et composition pour induire une neuroprotection

Country Status (9)

Country Link
US (1) US12611387B2 (https=)
EP (1) EP4142703B8 (https=)
JP (1) JP2023531869A (https=)
KR (1) KR20230013116A (https=)
CN (1) CN116981449A (https=)
CA (1) CA3178633A1 (https=)
ES (1) ES2970378T3 (https=)
FR (1) FR3110393B1 (https=)
WO (1) WO2021234324A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3149773B1 (fr) 2023-06-19 2026-04-17 Rest Therapeutics Nouvelles combinaisons synergiques a base de fenm
WO2026003229A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament
FR3163834A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine
FR3163835A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200418446A (en) * 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
MX2007004491A (es) * 2004-10-15 2007-08-08 Johnson & Johnson Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20120115943A1 (en) * 2008-10-01 2012-05-10 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
FR3006193B1 (fr) 2013-05-29 2015-06-19 Holis Technologies Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda)
FR3050732B1 (fr) 2016-05-02 2019-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS

Also Published As

Publication number Publication date
ES2970378T3 (es) 2024-05-28
FR3110393A1 (fr) 2021-11-26
CN116981449A (zh) 2023-10-31
US20230270695A1 (en) 2023-08-31
US12611387B2 (en) 2026-04-28
KR20230013116A (ko) 2023-01-26
EP4142703B1 (fr) 2023-10-18
JP2023531869A (ja) 2023-07-26
FR3110393B1 (fr) 2022-05-06
EP4142703B8 (fr) 2023-11-22
EP4142703C0 (fr) 2023-10-18
WO2021234324A1 (fr) 2021-11-25
EP4142703A1 (fr) 2023-03-08

Similar Documents

Publication Publication Date Title
EP4142703B1 (fr) Composé et composition pour induire une neuroprotection
Athar et al. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Zheng et al. Curcumin ameliorates memory decline via inhibiting BACE1 expression and β-Amyloid pathology in 5× FAD transgenic mice
Wirianto et al. The clock modulator Nobiletin mitigates astrogliosis‐associated neuroinflammation and disease hallmarks in an Alzheimer’s disease model
Zhang et al. Pathological impacts of chronic hypoxia on Alzheimer’s disease
Panza et al. Disease-modifying approach to the treatment of Alzheimer’s disease: From α-Secretase activators to γ-secretase inhibitors and modulators
Lai et al. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice
Companys-Alemany et al. NMDA receptor antagonists reduce amyloid-β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice
Mancuso et al. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before
Panza et al. Beyond the neurotransmitter-focused approach in treating Alzheimer’s disease: drugs targeting β-amyloid and tau protein
Buendia et al. Subthreshold concentrations of melatonin and galantamine improves pathological AD-hallmarks in hippocampal organotypic cultures
Zamani et al. Key mechanisms underlying netrin‐1 prevention of impaired spatial and object memory in Aβ1‐42 CA1‐injected rats
Weber et al. Killing two angry birds with one stone: autophagy activation by inhibiting calpains in neurodegenerative diseases and beyond
US20200164010A1 (en) Method for treating dementia
US10912819B2 (en) Neuroprotective peptides derived from activity-dependent neuroprotective protein for treatment of neurological diseases
Xiao et al. Uric acid mitigates cognitive deficits via TFEB-mediated microglial autophagy in mice models of Alzheimer’s disease
Roy et al. C-reactive protein: the nexus between inflammation and protein misfolding diseases
Beretta et al. Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K)
Carles et al. Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease
Joshi et al. Transient receptor potential channels as an emerging target for the treatment of Alzheimer's disease: Unravelling the potential of pharmacological interventions
Hensley et al. Autophagy modulation by lanthionine ketimine ethyl ester improves long-term outcome after central fluid percussion injury in the mouse
Viswanathan et al. Ubiquilin-1 modulates γ-secretase-mediated ε-site cleavage in neuronal cells
Xie et al. Acute transcriptomic and epigenetic alterations at T12 after rat T10 spinal cord contusive injury
Tan et al. Anti-Alzheimer therapeutic drugs targeting γ-secretase
Rong et al. Dual PDE4/10A inhibition restores CREB1 function and enhances neuronal resilience in models of alzheimer's disease

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250423

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250505

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250715

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250715

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250716

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260311

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260423